Asthma Market Assesses the Future Impact of the Propellants, Potential Demands and Restraints on the Market

Press Release

Asthma is a respiratory condition, where the airways become inflamed and narrow, which can cause a serious and incurable condition if left untreated. Breathlessness, wheezing and coughing are some of the symptoms of asthma and it can be controlled by avoiding triggers and with the help of drug therapy. Environmental triggers may vary from consumer to consumer but it can include exercise, smoke, cold air and other allergens such as pollen, dust mites, and infections. The wheezing in asthma begins when the chemicals present in the lungs overreact to the dust mites, cold air and exercise.

According to Centers for Disease Control and Prevention (CDC), asthma is an ordinary chronic airway disorder which is characterized by swelling of air passages that convey air from mouth and nose to lungs. Asthma is caused generally due to allergies leading to inflammation of lungs. GlaxoSmithKline Pharmaceuticals Limited and Novartis AG are developing once-a-day combination products that are longer acting than currently available drugs and more suitable for patients due to its advantage of being taken only once a day.

Request to Get the Sample Pages at:

Based on drug class, the global asthma market can be categorized bronchodilators, combination therapies, mast cell stabilizers, leukotriene antagonists and immunosuppressants. On the basis of route of administration, the global market is segmented into oral, inhaled and other route of administrations.

Country wise, U.S. and China are the two major markets of asthma. Growth in urbanization and change in lifestyle in China are the major factor for the increasing asthma in the country. The incidence of asthma symptoms is higher in urban areas as compared to rural areas due to factors such as air pollution and smoking, and it has led to the quick increase in asthma patients in China.

Some of the major competitors of global asthma market are, Ono Pharmaceutical Co., Ltd., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd. Merck & Co., Inc., Astrazeneca plc, Sunovion Pharmaceuticals, Inc., Novartis AG, Boehringer Ingelheim GmbH, Koninklijke Philips N.V., and F. Hoffmann La-Roche Ltd.

This post was originally published on Financial Sector

Comments are closed.